TIDMPRTC
PureTech Health PLC
22 May 2018
22 May 2018
PureTech Health plc
PureTech's Alivio Granted Two US Patents Broadly Covering
Compositions of Matter for Inflammation-Targeting Technology
Platform
PureTech Health plc (LSE: PRTC) ("PureTech Health"), an
advanced, clinical-stage biopharmaceutical company, announced today
that its affiliate, Alivio Therapeutics, has been granted two key
patents broadly covering its inflammation-targeting technology
platform.
Alivio's newest patents issued by the United States Patent and
Trademark Office (USPTO), Nos. 9,962,339 and 9,974,859, broadly
cover compositions of matter and other aspects of the
inflammation-targeting microfiber materials with embedded molecules
of interest. These patents lay a strong foundation for Alivio to
expand its intellectual property portfolio for this unique
technology platform. Both patents are exclusively licensed by
Alivio from Brigham and Women's Hospital and the Massachusetts
Institute of Technology.
Eric Elenko, PhD, Chief of Research and Strategy at PureTech
Health, said: "PureTech's mission is to pioneer new categories of
medicine that address serious chronic diseases in a highly targeted
manner. One area of focus for us is autoimmune disease, such as
inflammatory bowel disease and other inflammatory conditions, and
Alivio is pioneering inflammation-targeting technology to offer
safe and effective treatment options for patients living with these
challenging disorders. These new patents validate the uniqueness of
Alivio's approach and are foundational to this affiliate's growing
pipeline of targeted immunomodulation opportunities."
In April 2018, a preclinical study of Alivio's technology
platform was published in Nature Communications, demonstrating
proof-of-concept that an immunomodulatory drug, administered
locally using the Alivio inflammation-targeting technology,
substantially reduced measures of arthritis disease activity, with
a 5.7-fold improvement in the disease clinical score vs control, as
compared to only 1.4-fold for the free drug. In July 2017, Alivio
presented data for product candidate ALV-107 showing durable pain
control throughout a 24-hour study period, lasting at least 12
times longer than lidocaine at a comparable dose, in a validated
preclinical model for the treatment of interstitial
cystitis/bladder pain syndrome (IC/BPS).
The full text of the announcement from Alivio is as follows:
Alivio Therapeutics Announces Issuance of Two U.S. Patents
Broadly Covering Compositions of Matter for Inflammation-Targeting
Technology Platform
Boston, Massachusetts, May 22, 2018 - Alivio Therapeutics, an
affiliate of PureTech Health plc (LSE: PRTC) developing therapies
to treat inflammatory disorders through targeted disease
immunomodulation, today announced that the United States Patent and
Trademark Office (USPTO) issued U.S. Patent Nos. 9,962,339 and
9,974,859, related to the Company's inflammation-targeting
technology platform. The patents, among other aspects, broadly
cover compositions of matter of the inflammation-targeting
microfiber materials with embedded molecules of interest. The
platform is being evaluated for use across a variety of diseases,
including inflammatory bowel disease and pain.
The now patented technology is designed to administer
therapeutically-relevant molecules, such as small molecules,
biologics (e.g., antibodies, peptides, and proteins), and nucleic
acids, directly to site of inflammation, bypassing healthy tissue.
The Alivio technology is also engineered to respond dynamically to
the disease site, releasing the embedded therapeutics based on the
degree of inflammation present. This novel approach has the
potential to enable new paradigms for treating inflammatory disease
- both orally and via other administration routes - while
simultaneously minimising the risks of exposing healthy tissue to
potent immunomodulators.
"The USPTO's allowance of these broad claims is an independent
acknowledgment of the uniqueness of the technology and lays a
strong foundation for our intellectual property portfolio," said
Aleks Radovic-Moreno, PhD, PureTech Health Vice President and
Alivio programme lead. "Based on compelling preclinical data in
several independent disease models, we are developing potentially
important new drugs for a range of chronic and acute inflammatory
diseases, such as inflammatory bowel disease, arthritis, and
interstitial cystitis/bladder pain syndrome."
The relevant intellectual property is exclusively licensed to
Alivio Therapeutics and is based on technology developed by Jeffrey
Karp, PhD, Brigham and Women's Hospital (BWH), Harvard Medical
School (HMS), and Robert Langer, ScD, Massachusetts Institute of
Technology (MIT). The pioneering work of Dr Karp, Dr Langer, and
their colleagues has demonstrated selective modulation of the
immune system at the site of disease in relevant preclinical models
using therapeutic agents embedded in the Alivio microfibers. Alivio
is now advancing this promising inflammation-targeting technology
platform and building a robust pipeline with the goal of achieving
targeted disease immunomodulation to address a number of targeted
therapies for treating chronic and acute inflammatory diseases.
In April 2018, a preclinical study of Alivio's technology
platform was published in Nature Communications, demonstrating
proof-of-concept that an immunomodulatory drug, administered
locally using the Alivio technology, substantially reduced measures
of arthritis disease activity, with a 5.7-fold improvement in the
disease clinical score vs. control, as compared to only 1.4-fold
for the free drug. In July 2017, Alivio presented data for product
candidate ALV-107 showing durable pain control throughout a 24-hour
study period, lasting at least 12 times longer than lidocaine at a
comparable dose, in a validated preclinical model for the treatment
of interstitial cystitis/bladder pain syndrome (IC/BPS).
About Alivio
Alivio Therapeutics, an affiliate of PureTech Health (PRTC.L),
is pioneering targeted disease immunomodulation as a novel strategy
to treat a range of chronic and acute inflammatory disorders.
Targeted disease immunomodulation involves tuning the immune system
exclusively at the site of disease in the body, with minimal impact
on the rest of the immune system. This long sought-after approach
has potential to treat a range of chronic and acute inflammatory
disorders including ones that would otherwise be difficult to
treat. Alivio's proprietary inflammation-targeting technology,
based on the research of Dr Karp and Dr Robert Langer, David H.
Koch Institute Professor at MIT, is the first technology to
reproducibly show the ability to target immunomodulatory compounds
to inflamed tissue, which can lead to dramatic improvements in
treatment efficacy with major reductions in systemic effects. The
platform has been validated in multiple labs and in eight different
animal models of inflammation where the inflammation occurred in
different parts of the body (e.g., the GI system, the bladder,
joints, skin, etc.). The technology could potentially be used with
a variety of medications (e.g., small molecules, biologics, and
nucleic acids) both independently or in combination, and is
designed to be administered orally or via other routes. With this
platform, Alivio aims to address the dozens of conditions where
inflammation is a central part of the underlying disease pathology,
but where targeted and effective treatment options are lacking.
Alivio is developing its proprietary technology in collaboration
with several of the world's leading experts in biomaterials and
immunology. Expert advisors include: Jeffrey Karp, PhD, Professor
of Medicine at Brigham and Women's Hospital and Alivio co-founder;
Robert Langer, ScD, Co-Alivio Founder and Non-Executive Director at
PureTech Health and David H. Koch Institute Professor at MIT;
Michael B. Brenner, M.D., Chief of the Division of Rheumatology,
Immunology and Allergy at BWH; Ulrich H. von Andrian, MD, PhD,
Mallinckrodt Professor of Immunopathology at Harvard Medical
School; and Ralph Weissleder, MD, PhD, Director of the Center for
Systems Biology at Massachusetts General Hospital.
About PureTech Health
PureTech Health (PRTC.L) is an advanced, clinical-stage
biopharmaceutical company developing novel medicines targeting
serious diseases that result from dysfunctions in the nervous,
immune, and gastrointestinal systems (brain-immune-gut or the "BIG"
axis), which together represent the adaptive human systems.
PureTech Health is at the forefront of understanding and addressing
the biological processes and crosstalk associated with the BIG
axis. By harnessing this emerging field of human biology, PureTech
Health is pioneering new categories of medicine with the potential
to have great impact on people with serious diseases. PureTech
Health is advancing a rich pipeline of innovative therapies that
includes two pivotal stage programmes, multiple human
proof-of-concept studies and a number of early clinical and
pre-clinical programmes. PureTech's research and development
pipeline has been advanced in collaboration with some of the
world's leading scientific experts, who along with PureTech's team
of biopharma pioneers, entrepreneurs and seasoned Board, identify,
invent, and clinically de-risk new medicines. With this experienced
team pursuing cutting edge science, PureTech Health is building the
biopharma company of the future focused on improving and extending
the lives of people with serious disease. For more information,
visit www.puretechhealth.com or connect with us on Twitter
@puretechh.
Forward Looking Statement
This press release contains statements that are or may be
forward-looking statements, including statements that relate to the
company's future prospects, developments and strategies. The
forward-looking statements are based on current expectations and
are subject to known and unknown risks and uncertainties that could
cause actual results, performance and achievements to differ
materially from current expectations, including, but not limited
to, those risks and uncertainties described in the risk factors
included in the regulatory filings for PureTech Health plc. These
forward-looking statements are based on assumptions regarding the
present and future business strategies of the company and the
environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements,
neither the company nor any other party intends to update or revise
these forward-looking statements, whether as a result of new
information, future events or otherwise.
Contact:
Investors EU media U.S. media
Allison Mead Talbot Ben Atwell, Rob Tom Donovan
+1 617 651 3156 Winder +1 857 559 3397
amt@puretechhealth.com +44 (0) 20 3727 tom@tenbridgecommunications.com
1000
ben.atwell@FTIconsulting.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAEAFSFAEXPEAF
(END) Dow Jones Newswires
May 22, 2018 02:02 ET (06:02 GMT)
Puretech Health (LSE:PRTC)
Historical Stock Chart
From Apr 2024 to May 2024
Puretech Health (LSE:PRTC)
Historical Stock Chart
From May 2023 to May 2024